GTCR completed a $1.2bn investment in PathGroup.

GTCR, a private equity firm, completed a $1.2bn investment in PathGroup, a premier provider of anatomic, clinical and molecular pathology services. "Dr. Davis and the PathGroup team have done an incredible job of building PathGroup into a unique, scaled lab services business with outstanding clinical services. We look forward to supporting the team and expanding the PathGroup platform through organic growth initiatives and additional strategic acquisitions," Sean Cunningham, GTCR Managing Director and Co-Head of Healthcare.